Results 101 to 110 of about 489 (130)

Hypertrophic cardiomyopathy evolving management: American Heart Association/American College of Cardiology vs. European Society of Cardiology guidelines [PDF]

Olivotto, Iacopo
core   +1 more source

Diagnostic Ambiguity in Apical Hypertrophic Cardiomyopathy: Case-Based Insights and Review of Evolving Criteria. [PDF]

JACC Case Rep
Li-Jedras M, Hegazy Y, Abdul Jabbar AB, El-Shaer A, Ghallab M, Kabach A.   +5 more
europepmc   +1 more source

Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal. [PDF]

Future Cardiol
Keen S, Desai MY.
europepmc   +1 more source

Catastrophic apical ballooning in an obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report. [PDF]

Eur Heart J Case Rep
De Roeck F, Lahaye F, Gevaert AB, De Paep R, Van Craenenbroeck E.   +4 more
europepmc   +1 more source

Trusting the True Experts Through Patient-Reported Health Status in Hypertrophic Cardiomyopathy. [PDF]

J Am Coll Cardiol
Reza N.
europepmc   +1 more source

Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. [PDF]

Curr Cardiol Rep
Panichella G, Garofalo M, Ragagnin M, Fanizzi AI, Zampieri M, Del Franco A, Cappelli F, Pieroni M, Olivotto I.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

American Journal of Cardiovascular Drugs, 2023
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Based on the REDWOOD-HCM open label extension (OLE) study, participants receiving aficamten had significantly ...
Sneha Annie Sebastian, Inderbir Padda, Eric J. Lehr, Gurpreet Johal   +3 more
openaire   +2 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium. It further poses significant complications related to dynamic left ventricular outflow obstruction over time in
Jay, Patel, Andy, Wang, Sihari S, Naidu, William H, Frishman, Wilbert S, Aronow   +4 more
openaire   +2 more sources

Aficamten in non‐obstructive hypertrophic cardiomyopathy: Unlocking new horizons?

European Journal of Heart Failure
N ...
Rossi, Maddalena, Fabris, Enrico, Sinagra, Gianfranco   +2 more
openaire   +3 more sources